Skip to main navigation
  • Careers
  • Contact Us
Xen 01
  • About Us
    • Management
    • Partnering
    • Board of Directors
  • Pipeline
    • Obexelimab
    • Vibecotamab
    • Plamotamab
    • Tidutamab
    • XmAb717
    • XmAb841
    • XmAb104
  • Technology
    • Bispecific Fc Domains
    • Cytotoxic Fc Domains
    • Immune Inhibitor Fc Domains
    • Xtend Fc Domains
    • Publications
  • Clinical Trials
    • Expanded Access Policy
  • Investors
    • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financials & Filings
      • SEC Filings
      • Annual Reports
    • Analyst Coverage
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
    • Investor FAQs
    • Contact Us
    • Email Alerts

You are here:
Home / Investors / 4

Investor Relations

  • Investors
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Analyst Coverage
  • Stock Information
  • Investor FAQs
  • Contact Us
  • Email Alerts

Tools

Shareholder Tools

  • Snaphot
  • Print
  • Share
  • Facebook
  • LinkedIn
  • Twitter
  • RSS

SEC Filing Details

Document Details

Form
4
Filing Date
Mar 10, 2021
Document Date
Mar 8, 2021
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
Xencor, Inc.
Issuer
Xencor Inc
Filer
Yang Allen

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS
Xencor © Copyright 2021 | Privacy Policy
Scroll to top